


# BIOINFORMANT

## Global CAR-T Cell Therapy Market – Market Size, Forecasts, Trials & Trends



1ST AND ONLY MARKET RESEARCH FIRM TO  
SPECIALIZE IN THE STEM CELL INDUSTRY

**TABLE OF CONTENTS**

1. REPORT OVERVIEW	19
1.1 Statement of the Report	19
1.2 Executive Summary	21
1.3 Introduction	22
2. CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT	24
2.1 CAR-T Cell	25
2.2 Evolution of CAR-T Cell Development	26
2.2.1 The CAR-T Cell Family	26
2.2.1.1 First Generation CARs	27
2.2.1.2 Second Generation CARs	28
2.2.1.3 Third Generation CARs	28
2.2.1.4 Fourth Generation CARs	29
2.2.1.5 Fifth Generation CARs	29
2.3 Antigens Present on Hematological Malignant Cells	30
2.4 Tools for Inserting Receptor Genes into T Cells	31
2.5 Transforming T Cells into CAR-T Cells	32
2.6 The Seven CAR-T Therapies Available in the Market: A Brief Overview	33
2.7 Toxicities Associated with CAR-T Treatment	36
2.8 Strategies for the Future of CAR-T Therapies	37
2.8.1 Switchable CARs (sCARs)	38
2.8.2 Suicide Genes to Destroy CAR-T Cells In Vivo	39
2.8.3 Transient Transfection	39
2.8.4 Affinity Tuned CARs	39
2.8.5 Armored CARs	39
2.8.6 Shift from Liquid Cancers to Solid Tumors	40
2.8.7 Focus on Shortening Hospital Stay	40
2.8.8 Focus on Discovering New Antigens	41
2.8.9 Shifting from Autologous to Allogeneic CAR-T Therapies	41
2.8.10 CAR-T for the Masses	42
2.8.11 New In Vivo CAR-T Approach	42
2.8.12 Combination with mRNA Vaccine	43
2.8.13 Combination with Oncolytic Virus	43
2.9 Direct Competition between Autologous CAR-T Therapies	43
3. CAR-T CELL THERAPY: PRODUCT DEVELOPMENT	44
3.1 History of Development of CAR-T Cells	45
3.2 Top Ten Milestones Crossed by CAR-T Therapy	46
3.2.1 First Pediatric Patient to Receive CAR-T Therapy	46
3.2.2 CAR-T Granted Breakthrough Therapy Designation	46
3.2.3 The Beginning of CAR-T Development to Combat Solid Cancers	46
3.2.4 First CRISPR CAR-T Built	47
3.2.5 The First Two CAR-T Approvals	47
3.2.6 EMA's Approval for Kymriah and Yescarta	47
3.2.7 Approval of Tecartus, Breyanzi and Abecma	47
3.2.8 NMPA Approval of Relma-cel (Carteyva)	48

3.2.9	Approval of Carvykti	48	
3.3	Current Status of CAR-T Therapy Products		48
3.3.1	Kymriah (Tisagenlecleucel)	49	
3.3.1.1	Kymriah's Mechanism of Action	50	
3.3.1.2	Clinical Trials on Kymriah	51	
3.3.2	Yescarta (Axicabtagene ciloleucel)		51
3.3.2.1	Mechanism of Action	52	
3.3.2.2	Yescarta on Clinical Trials	53	
3.3.3	Tecartus (Brexucabtagene autoleucel)	53	
3.3.3.1	Tecartus Approvals	53	
3.3.3.2	Mechanism of Action	54	
3.3.3.3	Clinical Trials on Tecartus	54	
3.3.4	Breyanzi (Lisocabtagene maraleucel)	55	
3.3.5	Abecma (Idecabtagene vicleucel)	56	
3.3.5.1	Regulatory Approvals for Abecma	56	
3.3.5.2	Mechanism of Action	57	
3.3.5.3	Clinical Trials on Abecma	57	
3.3.6	Relma-Cel (Relmacabtagene autoleucel)		58
3.3.7	Carvykti (Ciltacabtagene autoleucel)	59	
3.3.7.1	Regulatory Approvals for Carvykti	60	
3.3.7.2	Mechanism of Action	60	
3.3.7.3	Clinical Trials on Carvykti	60	
3.4	Other Promising CAR-T Product Candidates		61
3.4.1	ALLO-501	62	
3.4.2	CTX-110	62	
3.4.3	UCART19	62	
3.4.4	AUT01	62	
3.4.5	JCARH125	63	
3.4.6	PBCAR20A	63	
3.4.7	UCART123	63	
3.4.8	PRGN-3006	63	
3.4.9	UCART22	64	
3.4.10	UCARTCS1	64	
3.5	Transformative Potential of CAR-T Therapy	64	
3.6	Cancer Population Addressed by CAR-T Therapy		65
3.7	Advantages of CAR-T Cell Therapy	65	
3.8	Disadvantages of CAR-T Therapy	66	
4.	SCALABLE MANUFACTURING OF CAR-T CELLS		67
4.1	The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies		67
4.2	The Evolution of CAR-T Cell Manufacturing Platforms	69	
4.2.1	Open vs. Closed Systems	69	
4.2.2	Manual Processing vs. Automation	70	
4.2.3	Autologous vs. Allogeneic Manufacturing	71	
4.4	Operating Expenses in Autologous CAR-T Manufacturing		71
4.5	Operating Expenses in Allogeneic CAR-T Manufacturing		72
5.	CAR-T TARGET ANTIGENS		74
5.1	CAR-T Target Antigens on Hematological Malignancies		74

5.2	CAR-T Target Antigens on Solid Tumors	75
5.3	Common Antigens Targeted by CAR-T Cells in Clinical Trials	76
5.3.1	Cluster of Differentiation 19 (CD19)	77
5.3.2	Mesothelin	77
5.3.3	B-Cell Maturation Agent (BCMA)	77
5.3.4	GD2	78
5.3.5	Glypican-3 (GPC3)	78
5.3.6	Cluster Differentiation-22 (CD22)	78
6.	CAR-T PATENT LANDSCAPE	79
6.1	Geographical Origin of CAR-T Patent Applications	81
6.2	Top Ten CAR-T Patent Jurisdictions	81
6.3	Affiliations of CAR-T Patent Applicants	82
6.4	Top 20 Companies in CAR-T Patent Landscape	83
6.5	Top 20 Research Centers in CAR-T Patent Landscape	84
6.6	Top Ten CAR-T Inventors	85
6.7	Top Five CAR-T Patents with Most Family Members	86
6.8	Top Five CAR-T Patents with Most Inventors in Co-Authorship	87
6.9	Top Five Patents with Most Co-Applicants	88
6.10	Top 5 CAR-T Patents with Most Co-Applicants	88
7.	CAR-T CLINICAL TRIAL LANDSCAPE	89
7.1	Most Addressed Indications in Clinical Trials	89
7.2	Current Focus of Ongoing Clinical Trials	89
7.3	Countries with Most Clinical Trials	89
7.4	Phase of Clinical Trial Studies	91
7.5	CAR-T Clinical Trials for Hematological Malignancies	91
7.6	Simultaneous Targets by One CAR-T	92
7.7	CAR-T Generations Used in Clinical Trials	93
7.8	CAR-T Clinical Trials Focusing on Solid Tumors	93
7.9	CAR-T Targeted Biomarkers in Clinical Trials	94
7.10	CAR-T Targeted Biomarkers in the U.S. Clinical Trials	95
7.11	CAR-T Targeted Biomarkers in Chinese Clinical Trials	96
7.12	CAR-T Targeted Indications in the U.S. Clinical Trials	97
7.13	Indications Addressed by CAR-T Clinical Trials in China	98
7.14	Hematological Malignancies v.s. Solid Cancers in CAR-T Clinical Trials	99
7.15	CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.	100
7.16	CAR-T Clinical Trial Sponsor Companies & Institutions in China	102
7.17	CAR-T Clinical Trial Sponsor Companies & Institutions in other Countries	105
7.18	Improved CAR-T Constructs in Clinical Trials	107
7.18.1	CAR-T with PD1Fc	107
7.18.2	CAR-T with Truncated with EGFR (EGFRt)	107
7.18.3	CAR-T with IL7 and CCL19	107
7.18.4	CAR-T with PD1/CD28 Switch Receptor	108
7.18.5	CAR-T with PD1 shRNA Expressing Cassette	108
7.18.6	CAR-T with CTLA-4/PD-1 Antibody	108
7.18.7	CAR-T with PD-1 Antibodies	108
7.19	Distribution of CAR-T Trials by Type of SeFv Used	114
7.20	Distribution of CAR-T Clinical Trials by Type of Vectors Used	114

8.	PUBLISHED CAR-T SCIENTIFIC PAPERS IN PUBMED.GOV & NIH FUNDING	116
8.1	PubMed.gov Published Papers on the Five Generation of CARs	116
8.2	PubMed.gov Papers Published on Autologous and Allogeneic CAR-Ts	117
8.3	Published CAR-T PubMed Papers on Solid & Liquid Cancers	118
8.4	NIH Funding for CAR-T Research in 2022	120
9.	DEALS IN CAR-T THERAPY SPACE	122
9.1	Most Recent CAR-T Deals	122
9.1.1	Autolus Therapeutics/Bristol Myers Squibb	122
9.1.2	ArsenalBio/Genentech	122
9.1.3	Chugai Pharmaceutical/Noile Immune Biotech	122
9.1.4	Roche/Poseida Therapeutics	123
9.1.5	Oxford Biomedica/Undisclosed U.S. Company	123
9.1.6	Immatics/Bristol Myers Squibb	123
9.1.7	Galapagos/CellPoint/AboundBio	124
9.1.8	Coeptis/University of Pittsburgh	124
9.1.9	Pregene/CellPont	124
9.1.10	Intellia/Kyverna	125
9.2	Funding for CAR-T Therapy in H1 2022	125
9.2.1	Neukio Bio	125
9.2.2	Arsenal Biosciences	125
9.2.3	Eyestem	126
9.2.4	Legend Biotech	126
9.2.5	Immuneel Therapeutics	126
9.2.6	Tessa Therapeutics	127
9.2.7	Elicera Therapeutics	127
9.2.8	Inceptor Bio	127
9.2.9	AvenCell Therapeutics	127
9.2.10	Ucello Therapeutics	128
9.2.11	Kyverna Therapeutics	128
10.	REIMBURSEMENT FOR CAR-T THERAPIES	129
10.1	Potential Barriers to CAR-T Treatments	129
10.1.1	Patient Barriers	129
10.1.2	Limited Number of Treatment Centers	129
10.1.3	Travel, Lodging & Meal Expenses	130
10.1.4	Utilization Management Policies	130
10.1.5	Out-of-Pocket Costs	130
10.1.6	Geography	131
10.1.7	Logistics of Follow-Up	131
10.1.8	Reimbursement Uncertainty	131
10.2	Manufacturer Challenges	132
10.2.1	Lingering Manufacturing Issues	132
10.2.2	Difficulties with Scaling Up	132
10.3	CAR-T Reimbursement Updated for FY 2023 IPPS Final Rule	133
10.3.1	Payment Changes for CAR-T Cases	133
10.3.2	High-Cost Outlier Payments	133
10.4	Use of 2021 Data to Establish Payment	133

10.4.1	Adjustment for Clinical Trial Cases	134
10.4.2	Product NTAP Decisions	134
10.5	Reimbursement for CAR-T Therapy in Europe	135
10.5.1	Cost Components of Pre- and Post-CAR-T Cell Therapy	136
10.5.2	Average Total Costs Pre- and Post CAR-T Cell Administration in E.U.	137
10.6	Outcomes-Based Reimbursement for CAR-T Therapies in Europe	137
10.6.1	France	137
10.6.2	Germany	138
10.6.3	Italy	139
10.6.4	Spain	139
10.6.5	Reimbursement for CAR-T Therapies in U.K.	140
10.7	CAR-T Cell Treated Patients Registered in EBMT Registry	140
11.	BLOOD CANCERS: INCIDENCE AND AVAILABLE TREATMENTS	142
11.1	Lymphoma	143
11.1.1	Hodgkin Lymphoma (HL)	143
11.1.2	Non-Hodgkin Lymphoma (NHL)	143
11.1.3	Difuse Large B Cell Lymphoma (DLBCL)	144
11.1.4	Follicular Lymphoma (FL)	144
11.2	Leukemia	144
11.2.1	Types of Leukemia	145
11.2.1.1	Acute Myeloid Leukemia (AML)	145
11.2.1.2	Acute Lymphoblastic Leukemia (ALL)	146
11.2.1.3	Chronic Myeloid Leukemia (CML)	146
11.2.1.4	Chronic Lymphocytic Leukemia (CLL)	146
11.2.1.5	Multiple Myeloma (MM)	147
11.3	Treatment Options for Blood Cancers	147
11.3.1	Chemotherapy	148
11.3.2	Radiation Therapy	149
11.3.3	Targeted Therapy	149
11.3.4	Stem Cell Transplantation	150
11.3.5	Immunotherapy	151
11.3.5.1	Monoclonal Antibodies (mAbs)	151
11.3.6	Adoptive Cell Transfer Therapy/T Cell Transfer Therapy	152
11.4	The Staggering Cost of Cancer Therapies	152
12.	MARKET ANALYSIS	154
12.1	Global Market for CAR-T Cell Therapy by Product	154
12.2	Global Market for CAR-T Therapy by Geography	158
12.3	Global Market for CAR-T Therapy by Indication	159
13.	BARRIERS & STRATEGIES FOR SUCCESS IN CAR-T 2.0 MARKET PLACE	161
13.1	Barriers to CAR-T 2.0 Commercial Success	161
13.2	Capacity Constraints	161
13.3	Competition among Manufacturers	161
13.4	Competition from other Treatments	162
13.5	Market Development Strategies for CAR-T 2.0	162
13.5.1	Effective Physician Education	162
13.5.2	Logistical Excellence	162

13.5.3	Evidence Generation	162
14.	CAR-T COMPANIES: AN OVERVIEW	163
14.1	Abintus Bio, Inc.	163
14.2	Adicet Bio	164
14.2.1	Gamma Delta T Cells	164
14.2.2	Proprietary Cell Platform Process	164
14.2.3	Pipeline	165
14.3	AffyImmune Therapeutics, Inc.	166
14.3.1	Affinity-Tuned CARs	166
14.3.2	Real-Time CAR-T Cell Monitoring	166
14.4	Alaunos Therapeutics, Inc.	167
14.5	Aleta BioTherapeutics	168
14.5.1	Aleta's CAR-T Engager Pipeline	168
14.6	Allogene Therapeutics	169
14.6.1	AlloCAR-T	169
14.7	Anixa Biosciences, Inc.	170
14.8	Appia Bio	171
14.9	Arbele Ltd.	172
14.9.1	AI-CAR-T/NK Cell Platform	172
14.10	Arcellx	173
14.10.1	D-Domain Technology	173
14.10.2	ddCAR	173
14.10.3	ARC-SparX	174
14.11	Artiva Biotherapeutics	175
14.11.1	Artiva's AlloNK Platform	175
14.11.2	Artiva's CAR-NK Platform	175
14.12	Atara Biotherapeutics	176
14.12.1	Technology	176
14.12.2	Atara's Robust Pipeline	177
14.13	Aurora BioPharma	177
14.14	Autolus Therapeutics plc	178
14.14.1	Technology	178
14.14.2	CAR-T Cell Production	178
14.14.3	Manufacturing	178
14.14.4	Autolus' Therapies in Development	179
14.14.5	obe-cel	179
14.15	AvenCell Europe GmbH	180
14.15.1	AvenCell's Proprietary Platforms	180
14.15.2	UniCAR	180
14.15.3	RevCAR	180
14.15.4	TCE	181
14.15.5	AvenCell's Clinical and Preclinical Pipeline	181
14.16	Aavocyte, Inc.	182
14.16.1	AAVOT Technology	182
14.16.2	Indications for AAVOT Therapy	183
14.17	Beam Therapeutics, Inc.	184
14.17.1	Base Editing Technology	184
14.18	Bellicum Pharmaceuticals	185

14.18.1	GoCAR Technology	185
14.18.2	CaspaCIDe Safety Switch	185
14.19	BioNTech	187
14.19.1	BioNTech's Engineered Cell Therapies	187
14.9.2	BNT211	187
14.19.3	BNT212	187
14.20	Biosceptre	188
14.20.1	nfP2X7188	
14.20.2	Biosceptre's Product Pipeline	188
14.21	bluebird bio	189
14.21.1	CAR-T Collaborations	189
14.21.2	Collaboration with Celgene	189
14.21.3	Collaboration with Bristol Myers Squibb	189
14.21.4	Collaboration with TC BioPharm	190
14.21.5	Collaboration with Inhibrx	190
14.21.6	Collaboration with PsiOxus	190
14.22	Bristol Myers Squibb/Celgene Corp.	191
14.22.1	Products	191
14.22.1.1	ABECMA (idecabtagene vicleucel)	191
14.22.1.2	Breyanzi (lisocabtagene maraleucel)	191
14.23	Cabaletta Bio	192
14.23.1	CAAR Technology	192
14.24	Carina Biotech	193
14.25	CARsgen Therapeutics	194
14.26	Cartesian Therapeutics	195
14.27	CARTherics Pty Ltd.	196
14.27.1	Technology	196
14.28	Cellectis	197
14.28.1	Product Candidates	197
14.29	CellPoint BV	198
14.30	Celularity, Inc.	199
14.30.1	P CAR-T	199
14.31	Celyad Oncology	200
14.31.1	Technologies	200
14.31.2	All-In-One Vector Approach	201
14.31.3	Pipeline	201
14.32	Century Therapeutics, Inc.	202
14.32.1	Century's Approach	202
14.32.2	Gene Editing Technology	203
14.32.3	Proprietary Allo-Evasion Technology	204
14.32.4	CAR and Protein Engineering	204
14.32.5	Common Engineered iPSC Progenitors	205
14.32.6	Streamlined Manufacturing	206
14.32.7	Century's Pipeline Overview	207
14.33	Clade Therapeutics	208
14.34	Coeptis Therapeutics, Inc.	208
14.34.1	SNAP CAR-T	208
14.35	Creative Biolabs	209
14.35.1	CAR-T Therapy Development	209



14.35.2	Biomarker Identification and Selection	209	
14.35.3	scFv Generation	210	
14.35.4	CAR-T Gene Packaging & Delivery	210	
14.35.5	Replication-Competent Virus Testing Service	210	
14.35.6	CAR Cell In Vitro Assay Service	211	
14.35.7	CAR-T Preclinical In Vivo Assay	211	
14.35.8	IND Development for CAR-T Cell Therapy	211	
14.35.9	GMP Production for CAR-T Products	211	
14.35.10	CAR-T Clinical Trials	212	
14.36	CRISPR Therapeutics	213	
14.36.1	CRISPR/Cas9 Immuno-Oncology Cell Therapy	213	
14.36.2	CRISPR/Cas9 Allogeneic CAR-T Design	213	
14.37	Curocell, Inc.	214	
17.37.1	OVIS Technology	214	
17.38	CytoSeek	215	
14.38.1	Technology	215	
14.38.2	Pipeline	215	
14.39	Cytovia Therapeutics	216	
14.39.1	Technology	216	
14.40	DiaCarta	217	
14.40.1	Personalized CAR-T Immunotherapy Platform	217	
14.41	Elicera Therapeutics AB218		
14.41.1	iTANK CAR-T Technology	218	
14.41.2	Elicera's Product Pipeline	218	
14.42	Eureka Therapeutics, Inc.	219	
14.42.1	Technology	219	
14.42.1.1	E-ALPHA Phage Display Platform	219	
14.42.1.2	ARTEMIS Cell Receptor Platform	219	
14.42.2	Eureka's Product Pipeline	220	
14.43	EXUMA Biotech Corp.	221	
14.43.1	TMR CAR-T Technology	221	
14.44	Fate Therapeutics, Inc.	222	
14.45	Gilead Sciences, Inc.	223	
14.45.1	CAR-T Products	223	
14.45.1.1	TECARTUS (Brexucabtagene autoleucel)	223	
14.45.1.2	Yescarta (Axicabtagene ciloleucel)	223	
14.45.2	CAR-T Programs	224	
14.46	Gracell Biotechnologies	225	
14.46.1	FasTCAR	225	
14.46.2	TruUCAR	226	
14.46.3	SMART CART	226	
14.46.4	Gracell's Clinical Pipeline	226	
14.47	IASO Biotherapeutics	227	
14.47.1	Technology Platforms	227	
14.47.1.1	Fully Human Antibody Discovery Platform (IMARS)	227	
14.47.1.2	High-Throughput Screening Platform for CAR-T Candidates	228	
14.47.1.3	Universal CAR-T Technology Platform	228	
14.47.1.4	Manufacturing Technology Platform	228	
14.47.2	IASO's Diverse Product Pipeline	228	

14.48	iCell Gene Therapeutics	230
14.48.1	CARvac Platform	230
14.48.2	T-Cell Targeted CARs	230
14.48.3	Non-Gene Edited Universal CARs	230
14.48.4	C-TPS1	231
14.48.5	Compound CARs	231
14.48.5	Pipeline	231
14.49	ImmPACT Bio	232
14.49.1	Technologies	232
14.49.1.1	Dual-Targeted CAR-T Cell Therapy	232
14.49.1.2	ICAR Dual Targeting Technology	233
14.49.1.3	TGF-B CARs Targeting TME	233
14.50	Immuneel Therapeutics, Pvt. Ltd.	234
14.51	Inceptor Bio	235
14.51.1	Inceptor's Technology Platforms	235
14.52	Interius BioTherapeutics	236
14.52.1	Core Technology	236
14.53	Janssen Biotech, Inc.	237
14.53.1	JNJ-4528	237
14.54	JW Therapeutics	238
14.54.1	Relma-cel (JWCAR029)	238
14.55	Kite Pharma (Gilead)	239
14.55.1	Kite's Technology	239
14.55.2	Kite's Marketed Therapies	239
14.55.2.1	Yescarta (Axicabtagene ciloleucel)	239
14.55.2.2	Tecartus (Brexucabtagene autoleucel)	240
14.55.3	Kite's Pipeline Cancer Therapies	241
14.56	Kuur Therapeutics	242
14.56.1	Kuur's Product Candidates	242
14.57	Kyverna Therapeutics	243
14.57.1	CAR-T Cells	243
14.57.1.1	SynNotch CAR-T Cells	243
14.57.1.2	SynReg T Cells	244
14.58	Legend Biotech	246
14.58.1	LCAR-B38M/JNJ-4528	246
14.59	Leucid Bio	247
14.59.1	Leucid's Science	247
14.59.2	Leucid's Product Pipeline	247
14.60	Luminary Therapeutics, Inc.	248
14.60.1	BAFF CAR-T	248
14.60.2	Universal Receptor	249
14.60.3	Luminary Therapeutics' Pipeline	249
14.61	Lyell Immunopharma, Inc.	250
14.61.1	Technologies	250
14.61.1.1	Gen-R Technology	250
14.61.1.2	Epi-R Technology	250
14.62	MaxCyte, Inc.	251
14.62.1	ExPERT Technology Platform	252
14.62.1.1	ATx	252

14.62.1.2	GTx	253	
14.62.1.3	STx	253	
14.62.1.4	VLx	254	
14.63	Minerva Biotechnologies Corporation		255
14.63.1	Autologous huMNC2-CAR44	255	
14.64	Mnemo Therapeutics	256	
14.64.1	Mnemo's Approach	256	
14.64.1.1	Mnemo's 1XX CAR	256	
14.65	Mustang Bio	257	
14.66	Neukio Biotherapeutics	258	
14.66.1	iPSC-CAR-NK Technology	258	
14.67	NKarta, Inc.	259	
14.67.1	Technology	259	
14.67.2	NKarta's Pipeline	260	
14.68	Noile-Immune Biotech	261	
14.68.1	PRIME Technology	261	
14.69	Novartis AG	262	
14.69.1	The Pioneers of CAR-T Cell & Gene Therapy	262	
14.69.2	Approval of Kymriah (tisagenlecleucel)	262	
14.70	Oncternal Therapeutics	263	
14.70.1	Oncternal's Product Pipeline	263	
14.71	Orna Therapeutics	264	
14.71.1	oRNA Circular RNA	264	
14.71.2	oRNA's Pipeline Products	264	
14.72	Oxford Biomedica plc	265	
14.72.1	LentiVector Platform	265	
14.72.2	LentiStable Platform	265	
14.72.3	Adeno-Associated Virus (AAV) Platform	266	
14.72.4	TRiP System	266	
14.73	PeproMene Bio, Inc.	267	
14.73.1	BAFFR CAR-T Cells	267	
14.73.2	Bispecific T Cell Engager (BiTE)	268	
14.73.3	CAR NK Cells	268	
14.74	Poseida Therapeutics, Inc.	270	
14.74.1	Platforms	270	
14.74.1.1	piggyBac	270	
14.74.1.2	Cas-CLOVER	271	
14.74.1.3	Gene Delivery	271	
14.74.1.4	TSCM Cells	271	
14.74.2	Pipeline Products	271	
14.74.2.1	P-BCMA-ALL01	272	
14.74.2.2	P-MUC1C-ALL01	272	
14.74.2.3	P-PSMA-ALL01	272	
14.74.2.4	Dual CAR Allogeneic Programs	272	
14.74.2.5	P-PSMA-101	273	
14.75	Precigen, Inc.	273	
14.75.1	Therapeutic Platforms	273	
14.75.1.1	UltraCAR-T	273	
14.75.1.2	AdenoVerse Immunotherapy	274	

14.75.1.3	ActoBiotics	275	
14.75.1.4	Multifunctional Therapeutics	275	
14.75.2	Technology Platforms	275	
14.75.2.1	UltraVector	275	
14.75.2.2	Sleeping Beauty System	276	
14.75.2.3	AdenoVerse	276	
14.75.2.4	UltraPorator	276	
14.75.2.5	RheoSwitch	276	
14.75.3	Precigen's Pipeline	276	
14.76	Precision Biosciences	277	
14.76.1	ARCUS Genome Editing	277	
14.76.2	Precision's CAR-T Immunotherapy Pipeline	278	
14.77	Prescient Therapeutics	279	
14.77.1	Technology	279	
14.77.1.1	OmniCAR	279	
14.77.1.2	CellPryme-M	279	
14.77.1.3	PTX-100	280	
14.77.1.4	PTX-200	280	
14.78	ProMab Biotechnologies, Inc.	281	
14.78.1	Products	281	
14.78.2	Services	281	
14.78.2.1	Cell Line Engineering Services	282	
14.78.2.2	Custom CAR-T Cell Development	282	
14.78.2.3	Custom CAR-NK Cell Development	283	
14.78.2.4	Custom CAR-Macrophage Cell Development	283	
14.78.2.5	Custom Gamma Delta T Cell Development	283	
14.78.3	Lentivirus Production	283	
14.78.4	mRNA-Lipid Nanoparticle Gene Delivery	284	
14.78.5	Cancer Stem Cell Line Services	284	
14.79	Quell Therapeutics, Ltd.	285	
14.79.1	Quell's Platform	285	
14.80	Sorrento Therapeutics, Inc.	286	
14.80.1	DAR-T (Dimeric Antigen Receptor T Cell)	286	
14.81	SOTIO Biotech, A.S.	287	
14.81.1	SOTIO's Pipeline	287	
14.82	Syngene International, Ltd.	288	
14.82.1	CAR-T Services	288	
14.83	Synthekine	290	
14.83.1	STK-009 + SYNCAR-001	290	
14.84	TC BioPharm	291	
14.84.1	Gamma Delta T Cells	291	
14.84.2	Cell Banks	292	
14.84.3	Co-Stim CAR-T	292	
14.84.4	TC BioPharm's Product Pipeline	292	
14.84.5	OmnImmune	293	
14.84.6	CAR-T Programs	293	
14.85	T-CURX	294	
14.85.1	CARAMBA Project	294	
14.85.2	imSAVAR Project	294	

14.86	Tessa Therapeutics, Ltd.	295
14.87	Tmunity Therapeutics	296
14.87.1	Technology	296
14.87.2	Pipeline	296
14.88	Umoja Biopharma	298
14.88.1	Umoja's Core Technology Platforms	298
14.88.1.1	VivoVec in vivo Gene Delivery	298
14.88.1.2	RACR/CAR in vivo Cell Programming	298
14.88.1.3	TumorTag (Universal CAR Tumor Targeting)	299
14.89	Vor Biopharma	300
14.89.1	Vor Biopharma's Approach	300
14.89.2	Vor's Platform	300
14.89.3	Vor's Pipeline	300
14.90	Wugen	302
14.91	WuXi Advanced Therapies	303
14.91.1	Closed-Process CAR-T Platform	303
14.92	Xenetic Biosciences	305
14.92.1	The DNase Platform Technology	305
14.92.2	XCART Personalized CAR-T Platform Technology	305
14.92.3	PolyXen PSA Technology Platform	306
14.93	Xyphos Biosciences, Inc.	307
14.93.1	ACCEL & UDC Technology	307
14.93.2	convertibleCAR	307
14.93.3	Universal Donor Cells	308

## **INDEX OF FIGURES**

FIGURE 2.1:	The Basic Structure of a T cell	24
FIGURE 2.2:	Binding of a T cell onto an Infected Cell	25
FIGURE 2.3:	Components of a CAR-T Cell	26
FIGURE 2.4:	The Three Domains of a CAR	27
FIGURE 2.5:	The First Generation CARs	27
FIGURE 2.6:	Second Generation CARs	28
FIGURE 2.7:	Third Generation CARs	28
FIGURE 2.8:	Fourth Generation CARs	29
FIGURE 2.9:	Fifth Generation CARs	30
FIGURE 2.10:	Antigens Present on Normal & Cancer Cells	30
FIGURE 2.11:	The Process of CAR-T Manufacturing	32
FIGURE 2.12:	Preparation & Administration of CAR-T Therapy	33
FIGURE 3.1:	The Five Generations of CARs	44
FIGURE 3.2:	A Package of Kymriah	50
FIGURE 3.3:	Yescarta in a Blood Bag	52
FIGURE 3.4:	Tecartus in a Blood Bag	54
FIGURE 3.5:	Abecma in a Blood Bag	57
FIGURE 3.6:	Relma-cel in a Blood Bag	58
FIGURE 3.7:	Carvykti in a Blood Bag	59
FIGURE 4.1:	The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies	68
FIGURE 4.2:	G-Rex Bioreactors	69

FIGURE 4.3: CliniMACS Prodigy	70
FIGURE 4.4: Scaling Up of Allogeneic CAR-T Cells	71
FIGURE 4.5: Operating Expenses in Autologous CAR-T Manufacturing	72
FIGURE 4.6: Operating Expenses in Allogeneic CAR-T Manufacturing	73
FIGURE 5.1: CAR-T Global Distribution in Clinical Trials	74
FIGURE 6.1: CAR-T Patent Publications	79
FIGURE 6.2: Granted CAR-T Patents	80
FIGURE 6.3: Geographical Origin of CAR-T Patent Applications	81
FIGURE 6.4: Top Ten CAR-T Patent Jurisdictions	82
FIGURE 6.5: Affiliations of CAR-T Patent Applicants	83
FIGURE 7.1: Percent Share of CAR-T Clinical Trials by Phase	91
FIGURE 7.2: Percent Share of Hematological Malignancy Types in CAR-T Clinical Trials	92
FIGURE 7.3: Simultaneous Targets by One CAR-T	92
FIGURE 7.4: CAR-T Generations Used in Clinical Trials	93
FIGURE 7.5: % Share of Ten Major Solid Tumor Indications in CAR-T Clinical Trials	94
FIGURE 7.6: Hematological Malignancies v.s. Solid Cancers in CAR-T Clinical Trials	100
FIGURE 7.7: Distribution of CAR-T Clinical Trials by ScFv Used	114
FIGURE 7.8: Distribution of CAR-T Clinical Trials by Type of Vectors Used	115
FIGURE 8.1: Number of Published CAR-T Papers in PubMed.gov	116
FIGURE 8.2: Published PubMed Papers on the Five Generations of CAR-Ts	117
FIGURE 8.3: Published PubMed Papers, Autologous v.s Allogeneic CAR-Ts	118
FIGURE 8.4: Published CAR-T PubMed Papers on Solid & Liquid Cancers	119
FIGURE 10.1: CAR-T Cell Treated Patients Registered in EBMT Registry	141
FIGURE 11.1: Global Incidence of Blood Cancers & Death in 2020	142
FIGURE 11.2: Percent Distribution of New Leukemia Cases in the U.S. by Type	145
FIGURE 12.1: Estimated Global Market for CAR-T Therapy by Product, 2022-2030	157
FIGURE 12.2: Global Market for CAR-T by Geography, 2021-2030	159
FIGURE 12.3: Global Market for CAR-T Therapies by Indication, 2021-2030	160
FIGURE 14.1: Proprietary Cell Platform Process	165
FIGURE 14.2: Atara's Differentiated Approach to Allogeneic Cell Therapy	176
FIGURE 14.3: Schematic of P CAR-T with TCR-KO	199
FIGURE 14.4: All-In-One Vector Approach	201
FIGURE 14.5: Century's Approach in Developing Drug Product	202
FIGURE 14.6: Century's Precision Gene Editing Technology	203
FIGURE 14.7: Century's Allo-Evasion Technology	204
FIGURE 14.8: Century's CAR Engineering	205
FIGURE 14.9: Century's Common Engineered iPSC Progenitors	206
FIGURE 14.10: Difference between Donor-Derived and iPSC-Derived Cell Expansion	207
FIGURE 14.11: OVIS Technology	214
FIGURE 14.12: FasTCAR vs. Conventional CAR-T Manufacturing Process	225
FIGURE 14.13: Schematic of CD19/CD20 CAR-T Technology	232
FIGURE 14.14: Schematic of SynNotch CAR-T Cells Recognizing Target Cells	244
FIGURE 14.15: Schematic of Reprogrammed SynReg T Cells Targeting Disease Tissues	245
FIGURE 14.16: Schematic of BAFF CAR-T's Action	248
FIGURE 14.17: ATx	252
FIGURE 14.18: GTx	253
FIGURE 14.19: STx	254
FIGURE 14.20: MaxCyte VLx	254
FIGURE 14.21: NKarta's Engineered CAR-NK Cell	259

FIGURE 14.22: Mechanism of Action of BAFFR CAR-T Cells	267
FIGURE 14.23: Mechanism of Action of BAFF-R BiTE	268
FIGURE 14.24: PeproMene's CAR NK Cells	269
FIGURE 14.25: UltraCAR-T Cell274	
FIGURE 14.26: WuXi's Closed-Process CAR-T Platform	304
FIGURE 14.27: Convertible CAR Parts	308
FIGURE 14.28: Universal Donor Cells	308

## **INDEX OF TABLES**

TABLE 2.1: Potential CAR-T Targeted Antigens Present on Hematological Malignancies	31
TABLE 2.2: Key Differences between the available Vectors	32
TABLE 2.3: The Seven CAR-T Therapies Available in the Market: A Brief Overview	34
TABLE 2.3: (CONTINUED)	35
TABLE 2.3: (CONTINUED)	36
TABLE 2.4: Toxicities Associated with CAR-T Treatment	37
TABLE 2.5: Strategies for the Future of CAR-T Therapies	38
TABLE 2.6: A Short List of ongoing CAR-T Studies on Solid Tumors	40
TABLE 2.7: New Target Antigens and New Target Cancers	41
TABLE 2.8: A Non-Comprehensive List of Allogeneic CAR-T Companies	42
TABLE 3.1: History of Development of CAR-T Cell Therapy	45
TABLE 3.2: Approved CAR-T Products, their Developers and Indications	49
TABLE 3.3: Other Promising CAR-T Product Candidates	61
TABLE 3.4: Increased CAR-T Activity	64
TABLE 3.5: Very Small Patient Population Addressed by CAR-T Therapy	65
TABLE 5.1: CAR-T Target Antigens on Hematological Malignancies	75
TABLE 5.2: CAR-T Target Antigens on Solid Tumors	76
TABLE 6.1: Top 20 Companies in CAR-T Patent Landscape	84
TABLE 6.2: Top 20 Research Centers in CAR-T Patent Landscape	85
TABLE 6.3: Top Twenty CAR-T Inventors	86
TABLE 6.4: Top Five CAR-T Patents with Most Family Members	87
TABLE 6.5: Top Five CAR-T Patents with Most Inventors in Co-Authorship	87
TABLE 6.6: Top Five Patents with Most Co-Applicants	88
TABLE 6.7: Top 5 CAR-T Patents with Most Co-Applicants	88
TABLE 7.1: Number of CAR-T Clinical Trials by Country	90
TABLE 7.2: Percent Target Distribution of CAR-T Clinical Trials	95
TABLE 7.3: CAR-T Targeted Biomarkers in the U.S. Clinical Trials	96
TABLE 7.4: CAR-T Targeted Biomarkers in Chinese Clinical Trials	97
TABLE 7.5: CAR-T Targeted Indications in the U.S. Clinical Trials	98
TABLE 7.6: CAR-T Targeted Indications in the U.S. Clinical Trials	99
TABLE 7.7: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.	101
TABLE 7.7: (CONTINUED)	102
TABLE 7.8: CAR-T Clinical Trial Sponsor Companies & Institutions in China	103
TABLE 7.8: (CONTINUED)	104
TABLE 7.8: (CONTINUED)	105
TABLE 7.9: CAR-T Clinical Trial Sponsor Companies & Institutions in other Countries	106
TABLE 7.10: Clinical Trials of Fourth, Fifth and Gene Edited CAR-Ts	109
TABLE 7.10: (CONTINUED)	110

TABLE 7.10: (CONTINUED)	111	
TABLE 7.10: (CONTINUED)	112	
TABLE 7.10: (CONTINUED)	113	
TABLE 8.1: A Short List of NIH Funding for CAR-T Research in 2022	120	
TABLE 8.1: (CONTINUED)	121	
TABLE 10.1: Hospital Reimbursement, Proposed & Final Rule FY 2022 and FY 2023		135
TABLE 10.2: List Prices of Kymriah and Yescarta in Europe	136	
TABLE 10.3: Cost Components of Pre- and Post-CAR-T Cell Therapy, in E.U.	136	
TABLE 10.4: Average Total Costs Pre- and Post CAR-T Cell Administration in E.U.		137
TABLE 10.5: Reimbursement for CAR-T Therapies in France	138	
TABLE 10.6: Reimbursement for CAR-T Therapies in Germany	138	
TABLE 10.7: Reimbursement for CAR-T Therapies in Italy	139	
TABLE 10.8: Reimbursement for CAR-T Therapies in Spain	139	
TABLE 10.9: Reimbursement for CAR-T Therapies in U.K.	140	
TABLE 11.1: Cost of Treating Blood Cancers	153	
TABLE 12.1: Estimated Global Market for CAR-T Therapy by Product, 2021-2030		157
TABLE 12.2: Global Market for CAR-T by Geography, 2021-2030	159	
TABLE 12.3: Global Market for CAR-T Therapies by Indication, 2021-2030		160
TABLE 14.1: Adicet's Broad Pipeline in Cancer	165	
TABLE 14.2: Affymimmune's Affinity-Tuned Pipeline Products	166	
TABLE 14.3: Alaunos' Advanced Platform Targeting Solid Tumors	167	
TABLE 14.4: Aleta's CAR-T Engager Pipeline in High Unmet Need Indications		168
TABLE 14.5: Allogene's AlloCAR-T Pipeline	169	
TABLE 14.6: Anixa's Product Pipeline	170	
TABLE 14.7: Arbele's Product Pipeline	172	
TABLE 14.8: Arcellx's Current Product Pipeline	174	
TABLE 14.9: Artiva's NK Cell Therapy Pipeline for Cancer	175	
TABLE 14.10: Atara's Robust Product Pipeline	177	
TABLE 14.11: Autolus' Therapies in Development	179	
TABLE 14.12: AvenCell's Clinical and Preclinical Pipeline	181	
TABLE 14.13: Beam's Product Pipeline	184	
TABLE 14.14: Bellicum's Pipeline of Investigational Immunotherapies	186	
TABLE 14.15: Biosceptre's Product Pipeline	188	
TABLE 14.16: Cabaletta's Autoimmune Therapy Candidates in Development		193
TABLE 14.17: Carina Biotech's Clinical Programs	193	
TABLE 14.18: CARsgen's Product Pipeline	194	
TABLE 14.21: Celyad's Diversified Pipeline	201	
TABLE 14.22: Century's Pipeline Overview	207	
TABLE 14.23: CRISPR Therapeutics' Immuno-Oncology Programs		213
TABLE 14.24: CytoSeek's Pipeline Product Candidates	215	
TABLE 14.25: Cytovia's Product Pipeline	216	
TABLE 14.26: Elicera's Product Portfolio	218	
TABLE 14.27: Eureka's Product Pipeline	220	
TABLE 14.28: EXUMA's Pipeline Assets	221	
TABLE 14.29: Fate's Product Pipeline	222	
TABLE 14.30: Gilead's Ongoing CAR-T Programs	224	
TABLE 14.31: Gracell's Clinical Pipeline	226	
TABLE 14.32: IASO's Diverse Product Pipeline	229	
TABLE 14.33: iCell Gene's Product Pipeline	231	



TABLE 14.34: ImmPACT Bio's Product Pipeline	233
TABLE 14.35: Inceptor's Diversified Cell Therapy Programs	235
TABLE 14.36: JW Therapeutics' Product Pipeline	238
TABLE 14.37: Kite's Pipeline Cancer Therapies	241
TABLE 14.38: Legend's Autologous Product Pipeline for Hematological Cancers	246
TABLE 14.39: Legend's Allogeneic Product Pipeline for Hematological & Solid Cancers	246
TABLE 14.40: Leucid's Product Pipeline	247
TABLE 14.41: Luminary's Product Pipeline	249
TABLE 14.42: Lyell's Diverse Pipeline Targeting Solid Tumor Cancers	251
TABLE 14.43: Minerva's Pipeline Products for Solid Tumors	255
TABLE 14.44: Mustang Bio's Five In Licensed CAR-T Programs	257
TABLE 14.45: NKarta's Product Pipeline	260
TABLE 14.46: Noile-Immune's PRIME-based Pipeline Products	261
TABLE 14.47: Oncernal's Product Pipeline	263
TABLE 14.48: oRNA's Pipeline Products	264
TABLE 14.49: Oxford Biomedica's CDMO Services Pipeline	266
TABLE 14.50: PeproMene's Product Pipeline	269
TABLE 14.51: Poseida's Allogeneic & Autologous Product Candidates	271
TABLE 14.52: Precigen's Pipeline	277
TABLE 14.53: Precision's CAR-T Immunotherapy Pipeline	278
TABLE 14.54: Quell's Pipeline	285
TABLE 14.55: SOTIO's Pipeline	287
TABLE 14.56: Tessa's Product Pipeline	295
TABLE 14.57: Tmunity's Product Pipeline	297
TABLE 14.58: Umoja's Product Pipeline	299
TABLE 14.59: Vor Biopharma's Product Pipeline against Blood Cancers	301
TABLE 14.60: Wugen's Product Pipeline	302
TABLE 14.61: Xenetic's Product Pipeline	306
TABLE 14.62: Xyphos' Product Pipeline	309

## About BioInformant:

BioInformant is the first and only market research firm to specialize in the Regenerative Medicine (RM) Industry.

BioInformant research has been cited by prominent news outlets that include Nature Biotechnology, the Wall Street Journal, CBS News, Yahoo Finance, Medical Ethics, AABB, Xconomy, and Vogue Magazine.

BioInformant serves Fortune 500 companies that include Pfizer, Goldman Sachs, and Beckton Dickinson, as well as industry start-ups and market leaders worldwide.

For more about our company and clients, visit [www.BioInformant.com](http://www.BioInformant.com).

